KRAS and neoplasm: KrasG12C;Trp53-driven mouse LUADs respond to sotorasib in a manner highly reminiscent of the clinical results described in the CodeBreaK100 phase I/II clinical trial (6, 27), indicating that this GEM tumor model effectively recapitulates the response of human tumors to pharmacological KRAS inhibition (6).